XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Oct. 31, 2021
Jul. 27, 2021
Mar. 31, 2021
Jul. 31, 2020
Apr. 30, 2020
Investments [Line Items]                  
Aggregate fair value investment $ 398,743   $ 398,743       $ 188,978    
Carrying value of long-term investment 0   0       100,563    
Other Investments [Member]                  
Investments [Line Items]                  
Aggregate fair value investment 7,900   7,900       $ 11,100    
Datavant Merger [Member]                  
Investments [Line Items]                  
Proceeds from sale of investment           $ 320,000      
Gain on measurement of investment $ 443,800   $ 443,800            
Datavant Merger Combined Company [Member] | Combined Company [Member]                  
Investments [Line Items]                  
Noncontrolling Interest, Ownership Percentage by Parent 17.00%   17.00%            
Arbutus Biopharma Corporation [Member]                  
Investments [Line Items]                  
Common stock Owned, Balance, Shares of Arbutus 38,847,462   38,847,462            
Preferred stock Owned, Balance, Shares of Arbutus         1,164,000   1,164,000    
Investment owned conversion from preferred stock into common stock         22,833,922        
Aggregate fair value investment $ 151,100   $ 151,100       $ 129,400    
Unrealized gain (loss) on investments $ (15,600) $ 16,300 $ 21,700 $ 98,700          
Closing price of common stock $ 3.89   $ 3.89       $ 3.33    
Equity method investment ownership percentage 27.00%   27.00%            
Sio Gene Therapies Inc [Member]                  
Investments [Line Items]                  
Ownership interest, percentage 25.00%   25.00%            
Aggregate fair value investment $ 24,000   $ 24,000       $ 48,500    
Unrealized gain (loss) on investments $ (16,300) $ (34,200) $ (24,500) 6,300          
Closing price of common stock $ 1.29   $ 1.29       $ 2.61    
Datavant Holdings, Inc [Member]                  
Investments [Line Items]                  
Aggregate fair value investment $ 215,700   $ 215,700     224,100     $ 99,000
Unrealized gain (loss) on investments $ (4,300)   $ (8,400)            
Preferred stock issued and sold               639,140  
Gain on deconsolidation       $ 86,500          
Carrying value of long-term investment           $ 100,600      
Datavant Holdings, Inc [Member] | Series B Preferred Stock [Member]                  
Investments [Line Items]                  
Preferred stock issued and sold                 13,411,311
Gross proceeds from issuance of stock                 $ 27,200
Preferred stock issued and sold                 1,065,234
Total purchase price                 $ 2,500
Issued relating to the conversion of certain liability instruments                 1,800,253